Log In
BCIQ
Print this Print this
 

Brimica Genuair, Duaklir Genuair, Aclidinium bromide/formoterol fumarate (KRP-AB1102F, LAS40464)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFixed-dose combination of aclidinium bromide with the long acting beta agonist (LABA) formoterol
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD))
PartnerAllergan plc;
Menarini Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$2,847.1M

$1,627.1M

$1,220.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today